Dreyling MH, Martinez-Climent JA, Zheng M, Mao J, Rowley JD, Bohlander SK. The t(10;11)(p13;q14) in the U937 cell line results in the fusion of the AF10 gene and CALM, encoding a new member of the AP-3 clathrin assembly protein family. Proc Natl Acad Sci U S A. 1996;93:4804–9.

CAS  Google Scholar 

Tebar F, Bohlander SK, Sorkin A. Clathrin assembly lymphoid myeloid leukemia (CALM) protein: localization in endocytic-coated pits, interactions with clathrin, and the impact of overexpression on clathrin-mediated traffic. Mol Biol Cell. 1999;10:2687–702.

CAS  Google Scholar 

Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer’s disease. Nat Genet. 2009;41:1088–93.

CAS  Google Scholar 

Lambert J-C, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer’s disease. Nat Genet. 2009;41:1094–9.

CAS  Google Scholar 

Carrasquillo MM, Belbin O, Hunter TA, Ma L, Bisceglio GD, Zou F, et al. Replication of CLU, CR1, and PICALM Associations With Alzheimer Disease. Arch Neurol. 2010;67 [cited 2021 Apr 24]. Available from: http://archneur.jamanetwork.com/article.aspx?doi=10.1001/archneurol.2010.147.

Lambert J-C, Zelenika D, Hiltunen M, Chouraki V, Combarros O, Bullido MJ, et al. Evidence of the association of BIN1 and PICALM with the AD risk in contrasting European populations. Neurobiol Aging. 2011;32(756):e11–5.

Google Scholar 

Schjeide B-MM, Schnack C, Lambert J-C, Lill CM, Kirchheiner J, Tumani H, et al. The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. Arch Gen Psychiatry. 2011;68:207–13.

CAS  Google Scholar 

Naj AC, Jun G, Beecham GW, Wang L-S, Vardarajan BN, Buros J, et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer’s disease. Nat Genet. 2011;43:436–41.

CAS  Google Scholar 

Chen LH, Kao PYP, Fan YH, Ho DTY, Chan CSY, Yik PY, et al. Polymorphisms of CR1, CLU and PICALM confer susceptibility of Alzheimer’s disease in a southern Chinese population. Neurobiol Aging. 2012;33(210):e1–7.

Google Scholar 

Liu G, Zhang S, Cai Z, Ma G, Zhang L, Jiang Y, et al. PICALM gene rs3851179 polymorphism contributes to Alzheimer’s disease in an Asian population. NeuroMolecular Med. 2013;15:384–8.

CAS  Google Scholar 

Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C, et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. 2013;45:1452–8.

CAS  Google Scholar 

Morgen K, Ramirez A, Frölich L, Tost H, Plichta MM, Kölsch H, et al. Genetic interaction of PICALM and APOE is associated with brain atrophy and cognitive impairment in Alzheimer’s disease. Alzheimers Dement. 2014;10:S269–76.

Google Scholar 

Gharesouran J, Rezazadeh M, Khorrami A, Ghojazadeh M, Talebi M. Genetic evidence for the involvement of variants at APOE, BIN1, CR1, and PICALM loci in risk of late-onset Alzheimer’s disease and evaluation for interactions with APOE genotypes. J Mol Neurosci. 2014;54:780–6.

CAS  Google Scholar 

Belcavello L, Camporez D, Almeida LD, Morelato RL, Batitucci MCP, de Paula F. Association of MTHFR and PICALM polymorphisms with Alzheimer’s disease. Mol Biol Rep. 2015;42:611–6.

CAS  Google Scholar 

Huang K-L, Marcora E, Pimenova AA, Di Narzo AF, Kapoor M, Jin SC, et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer’s disease. Nat Neurosci. 2017;20:1052–61.

CAS  Google Scholar 

Santos-Rebouças CB, Gonçalves AP, Dos Santos JM, Abdala BB, Motta LB, Laks J, et al. rs3851179 polymorphism at 5′ to the PICALM gene is associated with Alzheimer and Parkinson diseases in Brazilian population. NeuroMolecular Med. 2017;19:293–9.

Google Scholar 

Sun D-M, Chen H-F, Zuo Q-L, Su F, Bai F, Liu C-F. Effect of PICALM rs3851179 polymorphism on the default mode network function in mild cognitive impairment. Behav Brain Res. 2017;331:225–32.

CAS  Google Scholar 

Raj T, Li YI, Wong G, Humphrey J, Wang M, Ramdhani S, et al. Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer’s disease susceptibility. Nat Genet. 2018;50:1584–92.

CAS  Google Scholar 

Kunkle BW, Grenier-Boley B, Sims R, Bis JC, Damotte V, Naj AC, et al. Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet. 2019;51:414–30.

CAS  Google Scholar 

Jansen IE, Savage JE, Watanabe K, Bryois J, Williams DM, Steinberg S, et al. Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer’s disease risk. Nat Genet. 2019;51:404–13.

CAS  Google Scholar 

Zeng F-F, Liu J, He H, Gao X-P, Liao M-Q, Yu X-X, et al. Association of PICALM gene polymorphisms with Alzheimer’s disease: evidence from an updated Meta-analysis. Curr Alzheimer Res. 2019;16:1196–205.

CAS  Google Scholar 

Masri I, Salami A, El Shamieh S, Bissar-Tadmouri N. rs3851179G>a in PICALM is protective against Alzheimer’s disease in five different countries surrounding the Mediterranean. Curr Aging Sci. 2020;13(2):162–8.

CAS  Google Scholar 

Juul Rasmussen I, Tybjærg-Hansen A, Rasmussen KL, Nordestgaard BG, Frikke-Schmidt R. Blood–brain barrier transcytosis genes, risk of dementia and stroke: a prospective cohort study of 74,754 individuals. Eur J Epidemiol. 2019;34:579–90.

CAS  Google Scholar 

Marsh M, McMahon HT. The structural era of endocytosis. Science. 1999;285:215–20.

CAS  Google Scholar 

Ford MG, Pearse BM, Higgins MK, Vallis Y, Owen DJ, Gibson A, et al. Simultaneous binding of PtdIns (4,5) P2 and clathrin by AP180 in the nucleation of clathrin lattices on membranes. Science. 2001;291:1051–5.

CAS  Google Scholar 

Sorkin A, von Zastrow M. Endocytosis and signalling: intertwining molecular networks. Nat Rev Mol Cell Biol. 2009;10:609–22.

CAS  Google Scholar 

Treusch S, Hamamichi S, Goodman JL, Matlack KES, Chung CY, Baru V, et al. Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer’s disease risk factors in yeast. Science. 2011;334:1241–5.

CAS  Google Scholar 

Zhao Z, Sagare AP, Ma Q, Halliday MR, Kong P, Kisler K, et al. Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance. Nat Neurosci. 2015;18:978–87.

CAS  Google Scholar 

Vecchi M, Polo S, Poupon V, van de Loo JW, Benmerah A, Fiore D. Nucleocytoplasmic shuttling of endocytic proteins. J Cell Biol. 2001;153:1511–7.

CAS  Google Scholar 

Miller SE, Sahlender DA, Graham SC, Höning S, Robinson MS, Peden AA, et al. The molecular basis for the endocytosis of small R-SNAREs by the clathrin adaptor CALM. Cell. 2011;147:1118–31.

CAS  Google Scholar 

Baig S, Joseph SA, Tayler H, Abraham R, Owen MJ, Williams J, et al. Distribution and expression of picalm in Alzheimer disease. J Neuropathol Exp Neurol. 2010;69:1071–7.

CAS  Google Scholar 

Parikh I, Fardo DW, Estus S. Genetics of PICALM expression and Alzheimer’s disease. PLoS One. 2014;9:e91242.

Google Scholar 

Ando K, Brion J-P, Stygelbout V, Suain V, Authelet M, Dedecker R, et al. Clathrin adaptor CALM/PICALM is associated with neurofibrillary tangles and is cleaved in Alzheimer’s brains. Acta Neuropathol. 2013;125:861–78.

CAS  Google Scholar 

Kanatsu K, Morohashi Y, Suzuki M, Kuroda H, Watanabe T, Tomita T, et al. Decreased CALM expression reduces Aβ42 to total Aβ ratio through clathrin-mediated endocytosis of γ-secretase. Nat Commun. 2014;5:3386.

Google Scholar 

Zhang Y, Sloan SA, Clarke LE, Caneda C, Plaza CA, Blumenthal PD, et al. Purification and characterization of progenitor and mature human astrocytes reveals transcriptional and functional differences with Mouse. Neuron. 2016;89:37–53.

CAS  Google Scholar 

Tian Y, Chang JC, Fan EY, Flajolet M, Greengard P. Adaptor complex AP2/PICALM, through interaction with LC3, targets Alzheimer’s APP-CTF for terminal degradation via autophagy. Proc Natl Acad Sci U S A. 2013;110:17071–6.

CAS  Google Scholar 

Ando K, De Decker R, Vergara C, Yilmaz Z, Mansour S, Suain V, et al. Picalm reduction exacerbates tau pathology in a murine tauopathy model. Acta Neuropathol. 2020;139:773–89.

CAS  Google Scholar 

Rauch JN, Luna G, Guzman E, Audouard M, Challis C, Sibih YE, et al. LRP1 is a master regulator of tau uptake and spread. Nature. 2020;580:381–5.

CAS  Google Scholar 

Shibata M, Yamada S, Kumar SR, Calero M, Bading J, Frangione B, et al. Clearance of Alzheimer’s amyloid-ss (1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J Clin Invest. 2000;106:1489–99.

CAS  Google Scholar 

Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron. 2004;43:333–44.

CAS  Google Scholar 

Bell RD, Sagare AP, Friedman AE, Bedi GS, Holtzman DM, Deane R, et al. Transport pathways for clearance of human Alzheimer’s amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J Cereb Blood Flow Metab. 2007;27:909–18.

CAS  Google Scholar 

Deane R, Sagare A, Hamm K, Parisi M, Lane S, Finn MB, et al. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J Clin Invest. 2008;118:4002–13.

CAS  Google Scholar 

Jaeger LB, Dohgu S, Sultana R, Lynch JL, Owen JB, Erickson MA, et al. Lipopolysaccharide alters the blood-brain barrier transport of amyloid beta protein: a mechanism for inflammation in the progression of Alzheimer’s disease. Brain Behav Immun. 2009;23:507–17.

CAS  Google Scholar 

Hong H, Liu LP, Liao JM, Wang TS, Ye FY, Wu J, et al. Downregulation of LRP1 [correction of LPR1] at the blood-brain barrier in streptozotocin-induced diabetic mice. Neuropharmacology. 2009;56:1054–9.

CAS  Google Scholar 

Sagare AP, Bell RD, Zhao Z, Ma Q, Winkler EA, Ramanathan A, et al. Pericyte loss influences Alzheimer-like neurodegeneration in mice. Nat Commun. 2013;4:2932.

Google Scholar 

Winkler EA, Nishida Y, Sagare AP, Rege SV, Bell RD, Perlmutter D, et al. GLUT1 reductions exacerbate Alzheimer’s disease vasculo-neuronal dysfunction and degeneration. Nat Neurosci. 2015;18:521–30.

CAS  Google Scholar 

Malo N, Hanley JA, Cerquozzi S, Pelletier J, Nadon R. Statistical practice in high-throughput screening data analysis. Nat Biotechnol. 2006;24:167–75.

CAS  Google Scholar 

Shun TY, Lazo JS, Sharlow ER, Johnston PA. Identifying actives from HTS data sets: practical approaches for the selection of an appropriate HTS data-processing method and quality control review. J Biomol Screen. 2011;16:1–14.

CAS  Google Scholar 

Aldewachi H, Al-Zidan RN, Conner MT, Salman MM. High-throughput screening platforms in the discovery of novel drugs for neurodegenerative diseases. Bioengineering (Basel). 2021;8:30.

CAS  Google Scholar 

Lazic D, Sagare AP, Nikolakopoulou AM, Griffin JH, Vassar R, Zlokovic BV. 3K3A-activated protein C blocks amyloidogenic BACE1 pathway and improves functional outcome in mice. J Exp Med. 2019;216:279–93.

CAS  Google Scholar 

Montagne A, Nikolakopoulou AM, Zhao Z, Sagare AP, Si G, Lazic D, et al. Pericyte degeneration causes white matter dysfunction in the mouse central nervous system. Nat Med. 2018;24:326–37.

CAS  Google Scholar 

Guo H, Zhao Z, Yang Q, Wang M, Bell RD, Wang S, et al. An activated protein C analog stimu